Replies to post #386851 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Bill, here is a better answer to your question from the April 2020 NWBIO PR.

The data collection process is including certain epigenetic and genetic information that is recognized as important in Glioblastoma, such as MGMT methylation status. As part of this process, the Company has also identified a method that can potentially enable an additional important genetic factor — IDH mutation status — to be analyzed using bio samples collected years ago during the trial, and to be analyzed in the same timeframe as the data lock. This IDH mutation factor was unknown when the Company’s trial began and through much of the trial period, but has become recognized as very important in recent years.

https://nwbio.com/nw-bio-to-discuss-projected-schedule-for-data-lock-unblinding-and-top-line-data-from-its-phase-3-clinical-trial-at-annual-shareholder-meeting/


Now we know WHO, as of 2021, no longer considers GBM to include tumors with IDH mutation.
We also know, for years, Dr. Liau has suggested IDH mutant tumors are not GBM.
We also know, counter-intuitively, IDH mutant tumors are less likely to respond to targeted immune therapy because they have less mutations, in Dr. Liau’s view.